WoHIT

Propeller, Aptar partner to develop connected metered dose inhaler

Propeller, Aptar partner to develop connected metered dose inhaler

Propeller Health is teaming-up with global drug delivery systems provider Aptar Pharma to jointly develop the world's first integrated connected metered dose inhaler (cMDI), with a novel electronic dose counter. The device is currently available for licensing and is expected to enter clinical studies later this year.

Pressurized MDIs are the most common type of inhaler device on the market today, with over 600 million units manufactured globally. They deliver aerosolized medications such as bronchodilators, corticosteroids and combinations that are used daily by COPD and asthma patients. The Propeller-Aptar partnership will create the first connected inhaler, which is said to be the most significant improvement in MDIs since the industry added mechanical dose counters over ten years ago.

The new inhaler will combine Aptar MDI components and sensor technology with Propeller electronics directly into the inhaler housing.The new inhaler will combine Aptar MDI components and sensor technology with Propeller electronics directly into the inhaler housing, allowing for accurate and reliable monitoring of when each patient uses their inhaled medication. Information about the use of medications would be put to work as part of the Propeller digital system for patients and providers. Further, patients would benefit from apps, emails, text messages and other feedback to learn more about their disease, how to better manage it, and how to stay on track with their prescribed dosing instructions. Physicians, on the other hand, would be able to identify individuals who need more help controlling symptoms, while care managers could focus on higher risk patients who need more personalized attention.

"We expect our connected inhaler to become the cornerstone for a platform of digital programs that will support and encourage better management of and quality of life with chronic respiratory disease," David Van Sickle, CEO of Propeller. "Together I believe we have the scale and expertise to impact millions of patients with asthma and COPD around the world."

Propeller's platform is 510(k) cleared and compatible with a majority of MDIs on the market today including controller medications such as GSK's Flovent, Merck's Dulera, Teva's QVAR, and others, as well as reliever medications such as GSK's Ventolin HFA, Merck's Proventil HFA, Teva's ProAir HFA, and generic albuterol. It is also cleared and compatible with medications utilizing Boehringer Ingelheims's RESPIMAT soft mist inhaler (SMI) and GSK's Diskus dry powder inhaler (DPI).

Leave a Reply

Top